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Breast lesions comprise a family of heterogeneous entities with variable patterns of presentation, 
morphology and clinical behaviour. The majority of breast lesions are traditionally classified into 
benign and malignant conditions and their behaviour can, in the vast majority of cases, be 
predicted with a reasonable degree of accuracy. However, there remain lesions which show 
borderline features and lie in a grey-zone between benign and malignant as their behaviour cannot 
be predicted reliably. Defined pathological categorisation of such lesions is challenging and for 
some entities is recognised to be subjective and include a range of diagnoses, and forms of 
terminology, which may trigger over-treatment or under-treatment. The rarity of these lesions 
makes acquisition of clinical evidence problematic and limits the development of a sufficient 
evidence base to support informed decision making by clinicians and patients. Emerging 
molecular evidence is providing a greater understanding of the biology of these lesions, but this 
may or may not be reflected in their clinical behaviour. Herein we discuss some breast lesions that 
are associated with uncertainty regarding classification, behaviour and hence management. These 
include biologically invasive malignant lesions associated with uncertain metastatic potential such 
as low-grade adenosquamous carcinoma, low-grade fibromatosis-like spindle cell carcinoma and 
encapsulated papillary carcinoma. Other lesions remain of uncertain malignant nature such as 
mammary cylindroma, atypical microglandular adenosis, mammary pleomorphic adenoma and 
infiltrating epitheliosis. The concept of categories of 1) breast lesions of uncertain malignant 
nature and 2) breast lesions of limited metastatic potential, are proposed with details of which 
histological entities could be included in each category, and their management implications are 
discussed.
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BACKGROUND
Mammary glandular cells show a high degree of phenotypic plasticity, which is reflected in 
the diverse morphology of lesions of a normal, reactive, hyperplastic and neoplastic 
nature1–4. In normal breast tissue, molecular studies have demonstrated the presence of 
distinct cellular subtypes, namely mature luminal/glandular cells and myoepithelial cells, 
and in addition to basal stem/progenitor cells and luminal progenitor cells5, 6. Normal 
mammary epithelial cells may show several types of differentiation (apocrine, clear cell, 
squamous, sebaceous, and mucinous) and alterations such as hypersecretory/lactational 
change. The majority of these cells lack hormone receptor expression [6, 7]. Mammary 
myoepithelial cells can also show a wide range of morphological appearances including 
epithelioid, spindle, myoid and clear cells. In hyperplastic lesions, aberrant differentiation of 
myoepithelial cells may be observed such as in collagenous spherulosis. Aberrant stromal 
changes are also seen in benign and malignant lesions. It is recognised that malignant breast 
tumours demonstrate a wide range of differentiation pathways with associated molecular and 
phenotypic diversity2, 7.
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Management of breast lesions is based on recognised features which have been shown to 
relate to the nature and the expected behaviour of the lesion. Benign tumours are usually 
managed conservatively. Malignant tumours invariably trigger interventions aimed at 
preventing progression and recurrence. In malignant mammary epithelial lesions, the 
presence of myoepithelial cells and basement membrane components at the epithelial-
stromal interface typically denotes that the lesion is in-situ and by inference lacks metastatic 
potential and therefore no systemic therapy is indicated. Malignant epithelial cells 
infiltrating the surrounding tissue with no evidence of peripheral myoepithelial cells are 
usually designated as invasive tumours and by inference will have metastatic ability, to a 
variable degree, and are candidates for systemic therapy directed by their prognostic and 
predictive characteristics.
In diagnostic breast pathology it is usually easy to identify and differentiate between benign 
and malignant lesions. The criteria of malignancy are well defined in most settings. 
Although some tumours may express some but not all features characteristic of malignancy, 
it is generally accepted that certain clinicopathological criteria in isolation can be used to 
define malignancy such as development of tumour metastasis, lymphovascular invasion or 
anaplasia of the primary tumour. However, there remain some lesions showing equivocal 
histological features intermediate between benign and malignant tumours and other lesions 
showing malignant histological features but lack evidence of clinically significant metastatic 
behaviour. Diagnostic categorisation and management of these lesions are problematic. 
Differences of opinion between pathologists as to whether a lesion is benign or malignant 
may lead to completely different management recommendations for the patient. Pathologists 
are well aware that clinicians prefer binary well-defined diagnostic categories to guide 
treatment decision. A borderline lesion without a clear diagnostic conclusion about whether 
the lesion is benign or malignant may make the choice of appropriate management 
challenging. This uncertainty may result in over-treatment or under-treatment and the same 
lesion may be treated differently in different centres or even in the same centre when 
managed by different clinicians. Aside from the psychological and social implications, a 
malignant diagnosis may result in offering systemic therapy with associated cost and side 
effects. In contrast a benign diagnosis may result in no further action. Management 
strategies should be based on an individual lesion’s risk and understanding of the benefits of 
intervention.
Such borderline grey-zone lesions which are difficult to categorise as benign or malignant 
due to the lack of evidence of their behaviour and lack of consensus on their diagnostic 
criteria are rare but exist (Tables 1&2). These may be divided into two broad categories:
1. Lesions that show biological and/or histological evidence of invasive 
malignancy, but are associated with negligible or very low incidence of 
metastasis. Examples of these lesions include pure low-grade 
adenosquamous metaplastic carcinoma, pure low-grade fibromatosis-like 
metaplastic breast carcinoma, encapsulated papillary carcinoma, 
borderline phyllodes tumour and atypical adenomyoepithelioma8–13. The 
first two lesions often show immunohistochemical and molecular features 
of basal-like/metaplastic breast carcinomas, and when diagnosed as frank 
Rakha et al. Page 3
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
invasive carcinoma, they are likely to trigger treatment similar to other 
aggressive triple-negative/basal metaplastic carcinomas. Diagnosing and 
designating such breast lesions as being of uncertain metastatic potential 
should trigger treatment focused on local control without the need for 
axillary node sampling or systemic therapy. Although their very low risk 
of metastatic potential should be acknowledged, available evidence does 
not support use of conventional forms of adjuvant systemic therapy.
2. Lesions with uncertain malignant nature that show some features 
characteristic of malignancy in the breast such as infiltrative margins and 
absence of peripheral myoepithelial cells, but lack other features such as 
cytonuclear atypia, lymphovascular invasion or evidence of metastasis. 
Examples of these entities include infiltrating epitheliosis, atypical 
microglandular adenosis, bland-looking skin adnexa-like and salivary 
gland-like tumours including non-cutaneous mammary pleomorphic 
adenoma and cylindroma14–16. The uncertain nature and the difficulty in 
categorisation of these lesions should be emphasized and acknowledged 
rather than arbitrarily allocating them to a definite malignant or definite 
benign category. Similar lesions of uncertain malignant nature have been 
reported in the thyroid17, 18, liver19 and smooth muscle20. Management of 
such lesions can be similar to benign tumours but should trigger ablative 
surgical excision with or without follow-up. Although the probability of 
local recurrence cannot be excluded, available evidence does not support 
the use of adjuvant systemic therapy or local radiation therapy. 
Recognising the uncertain nature of such lesions can also help the 
approach when they are identified on core biopsies. Additionally, this 
classification highlights the need for further studies to improve 
understanding of their nature and behaviour.
Herein, we briefly discuss the current evidence regarding the nature, behaviour and 
diagnostic categorization of these lesions. However, it is important to recognise that the list 
of such lesions discussed in this article is not exhaustive. Although risk lesions such as 
atypical ductal hyperplasia and atypical lobular hyperplasia are associated with potential risk 
of progression to invasive carcinoma, these lesions are well-recognised and their biological 
nature, diagnostic criteria and clinical behaviour have been defined. Similarly although some 
malignant breast lesions such as pure tubular and secretory carcinoma are associated with 
low metastatic potential, the malignant nature of these lesions is well-defined and clinical 
evidence to support their management exists21. These lesions are not discussed in this 
review.
BREAST LESIONS OF LIMITED METASTATIC POTENTIAL
1-Encapsulated and solid papillary carcinoma
Several independent studies have demonstrated biological invasive nature of encapsulated 
and solid papillary carcinoma lacking peripheral myoepithelial cells13, 22–24. Although there 
is a consensus to manage these lesions as a form of in situ carcinoma, equivalent to DCIS23, 
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nodal positivity and distant metastatic spread have been reported despite being extremely 
rare events that are too infrequent to justify use of adjuvant systemic therapy13, 23. In 
addition to the uncertain clinical behaviour of encapsulated and solid papillary carcinomas, 
some of these lesions show worrying histological features such as focal deficiency of the 
peripheral capsule, focal ragged margin, irregular outlines of some of the papillary clusters 
and presence within fat making histological diagnosis and differentiation from conventional 
invasive carcinoma more problematic as none of these features can definitively indicate 
invasion or predict behaviour. This inconsistency between histological features and 
biological evidence coupled with clinical evidence of indolence make diagnosis and 
management of these lesions subjective and dependent on the reporting pathologists’ 
perception of the degree of risk. Recognizing the uncertain/negligible risk of metastasis may 
overcome this problem and change the attitudes of pathologists, clinicians and patients 
towards their management and expectation of behaviour and outcome.
It is important to emphasise that the current evidence supporting the management of these 
lesions as an in situ disease concerns cases showing typical features characteristic of low and 
intermediate grade encapsulated and solid papillary carcinoma in situ13, 23. Rare variants 
such as high grade tumours25, encapsulated and solid papillary carcinoma with focal 
invasive micropapillary pattern or mucinous carcinoma-like areas and those infiltrating 
skeletal muscle13 are likely to behave as more typical forms of invasive breast 
adenocarcinoma. Further studies of the diagnostic criteria and behaviour of such rare 
variants are warranted. Encapsulated and solid papillary carcinoma associated with 
conventional invasive mammary-type carcinoma should be managed according to the 
conventional invasive component.
2-Low-grade adenosquamous carcinoma
Low-grade adenosquamous carcinoma (LG-ASC) is a rare form of infiltrative breast tumour 
that commonly arises in association with benign proliferative complex sclerosing and 
papillary breast lesions11. Sometimes there appear to be immunoreactive myoepithelial cells 
at the edge of some tumour islands. Overlapping features between these associated benign 
proliferative lesions and LG-ASC exist26. Adenosquamous proliferation, stromal changes 
and even clusters of lymphocytes are seen within these benign proliferative lesions and are 
often described as reactive mimics or attributed to earlier biopsy. Differentiating benign 
proliferative lesions showing these features from LG-ASC is often subjective. Previous 
studies have demonstrated that adenosquamous proliferation of reactive-looking lesions is 
morphologically and immunohistochemically indistinguishable from the neoplastic ducts of 
LG-ASC27. Pure LG-ASC has a favourable prognosis28. Histologically LG-ASC needs to be 
differentiated from pure tubular carcinoma, adenomyoepithelioma and syringomatous 
tumour of the nipple29 while clinically it should be differentiated from the high-grade forms 
of metaplastic carcinoma and other triple negative/basal-like carcinomas that are associated 
with an aggressive behaviour30. A recent study reported molecular similarity between low-
grade adenosquamous carcinoma and syringomatous tumour of the nipple29.
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3-Low grade fibromatosis-like metaplastic carcinoma
Low-grade fibromatosis-like spindle cell carcinoma (LG-FLSCC) is a variant of spindle cell 
carcinoma that is associated with a favourable prognosis31. Local recurrence can occur after 
local excision and distant metastases occur occasionally31, 32. LG-FLSCC is characterized 
by the proliferation of low-grade, cytologically bland spindle cells, which compose at least 
95% of the total tumour area and histologically resemble fibromatosis31, 33. Differentiation 
between these two entities in routine practice is often based on expression of epithelial 
markers by LG-FLSCC. In low-grade bland-looking spindle cell lesions of the breast, focal 
expression of epithelial differentiation markers (e.g., cytokeratins) is used to indicate 
malignancy regardless of other morphological features such as size, in-situ components or 
lymphovascular invasion34, 35.
In a recent copy number analyses study, Takano et al36 demonstrated that LG-FLSCCs are 
characterised by low genomic instability, and share no copy number aberrations with other 
metaplastic carcinomas. They suggested that this entity is a unique group of tumours and 
their genotype belies their apparent homogeneous morphology and phenotype36. Despite the 
indolent behaviour of LG-FLSCC akin to some locally aggressive lesions with very low 
metastatic potential31, 33, such as fibromatosis, a malignant diagnosis using the term 
carcinoma or metaplastic carcinoma with triple negative status may trigger inappropriate use 
of aggressive adjuvant systemic chemotherapy 31, 34.
Importantly for LG-ASC and LG-FLSCC to be recognised as malignant lesions of uncertain 
metastatic potential, the lesion should be pure with no evidence of node metastasis or of a 
locally advanced nature at the time of diagnosis12.
4- Borderline Phyllodes Tumour and Atypical adenomyoepithelioma
Histological and molecular features of phyllodes tumour and adenomyoepithelioma have 
been described in detail elsewhere8, 37–42. Although the majority of ademomyoepitheliomas 
and a large proportion of phyllodes tumours can be categorised as benign or malignant 
tumours, some tumours show intermediate histological features and discrimination is often 
difficult. The behaviour of these lesions is often unpredictable as they show some, but not all 
features of malignancy10, 41–43.
Although the risk of distant metastasis has been mainly been observed in histologically 
malignant phyllodes tumours8, 42, microscopic distinction between borderline and malignant 
phyllodes can be difficult and prediction of behaviour is consequently unreliable. In some 
studies, risk of metastasis was related to individual histological features and not restricted to 
the histological subtyping of malignant versus borderline tumours44–46. Rare events of 
metastasis have also been reported for lesions histologically diagnosed as borderline 
phyllodes tumours47–49.
Diagnostic features of atypical adenomyoepithelioma remain less well defined8, 37–42. 
Mitoses, cytonuclear atypia and infiltration attest to the malignant nature of the neoplastic 
myoepithelial cells in adenomyoepithelioma. However, these features remain subjective and 
less clearly defined9, 42, for example cases showing significant cytonuclear atypia may not 
demonstrate sufficient mitotic count for a diagnosis of malignancy as previously reported41. 
Rakha et al. Page 6
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
We have seen and others10, 41 have reported adenomyoepitheliomas showing features not 
sufficient for a malignant diagnosis as atypical adenomyoepithelioma, that have later 
developed metastasis. Therefore in view of the lack of defined diagnostic histological 
criteria that can predict clinical behaviour, we propose to consider borderline phyllodes 
tumour and atypical adenomyoepithelioma as lesions of uncertain metastatic behaviour to 
emphasise the uncertainty related to their behaviour.
BREAST LESIONS OF UNCERTAIN MALIGNANT NATURE
1- Infiltrating epitheliosis
Infiltrating epitheliosis (IE) is a rare lesion, first described by John Azzopardi15, that mimics 
carcinoma and is becoming increasingly recognized. IE is characterized by infiltrating 
epithelial islands, solid clusters, ducts and duct-like structures immersed in a scleroelastotic 
stroma. Proliferating cells feature architectural and cytological patterns and 
immunohistochemical profile reminiscent of those of usual ductal hyperplasia (UDH)15. The 
infiltrative nature and the lack of peripheral myoepithelial cells raise the concern that IE is a 
form of invasive low-grade malignant neoplasm, with some similarities to LG-ASC 
carcinoma (see above). Emerging molecular data have provided some evidence that these 
lesions are clonal and neoplastic rather than hyperplastic50. However, the immunoprofile, 
benign cytonuclear features, the absence of an in situ carcinoma and focal preservation of 
peripheral myoepithelial cells51 support the current view that IE is a form of benign 
exaggerated hyperplastic process, related to radial scar and complex sclerosing lesions, with 
aberrant expression of certain biomarkers that drive the effacement of myoepithelial cells. 
Focal reactive epithelial proliferative processes can be seen in some sclerosing lesions but 
usually to a lesser degree and with maintenance of peripheral myoepithelial cells. Eusebi and 
Millis52 proposed that IE should be regarded a probable risk marker for carcinoma. As the 
number of published cases is too few to provide sufficient clinical evidence to describe their 
nature, the uncertain behaviour of this lesion needs to be emphasised.
2-Low-grade lesions showing skin adnexa or salivary gland-like differentiation
Similarities in the embryogenesis of the breast and salivary gland (SG) and the dual 
epithelial–myoepithelial cell differentiation in both sites may account for the occurrence of 
salivary gland-type neoplasms in the breast.53 Salivary gland-like primary breast neoplasms 
are well documented including adenoid cystic carcinoma, acinic cell carcinoma and 
pleomorphic adenoma (PA). The fact that lesions in the breast and salivary glands are 
histologically similar however does not mean they have the same biology54–56 Chromosomal 
translocations are described in salivary gland PA57, 58, but such translocations have not been 
identified in breast PA59. Similarly some breast non-cutaneous lesions show skin adnexal 
type differentiation such as cylindroma. Here we discuss non-cutaneous mammary PA and 
cylindroma as two examples of breast lesions of uncertain malignant potential.
A-Mammary Pleomorphic Adenoma (PA)
PA of the breast is a rare neoplasm that frequently occurs in the retroareolar region. It 
presents as a circumscribed lesion characterised by a mixture of cells featuring epithelial and 
myoepithelial phenotypes embedded in an abundant stroma with myxoid, chondroid, or 
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osseous metaplasia.60 In the breast, PA has to be distinguished from matrix-producing 
metaplastic carcinoma, adenomyoepithelioma and papilloma with cartilaginous 
metaplasia.59, 61–63.
The reported indolent clinical behaviour of breast PA may support their benign nature 59. 
However local recurrences of breast PA have been reported64–66 and cytologically malignant 
features characteristic of conventional mammary-type carcinomas have been demonstrated 
and categorised as “carcinoma ex pleomorphic adenoma”67. Lymphovascular invasion68 and 
distant metastasis69–74 have been reported in histologically benign salivary gland PA. 
Absence of peripheral myoepithelial cells is a feature of breast PA. We believe that the lack 
of cytological atypia, mitotic activity and focal preservation of peripheral myoepithelial cells 
represent features of indolence as seen in other low-grade malignant tumours akin to low-
grade adenoid cystic carcinoma and low-grade matrix-producing MBC, rather than features 
defining benign biological nature of a breast tumour75. Moreover, circumscription is not 
always a feature of benign tumours. Some malignant breast tumours including high grade 
invasive carcinomas show pushing well-defined margins. The prominent stromal 
components with abundant chondroid or osseous metaplasia, comparable to matrix 
producing metaplastic carcinoma, also cannot be used to differentiate benign from malignant 
lesions. Such changes are seen in both benign and malignant tumours of the breast35. The 
characteristic immunohistochemical profile of breast PA with the triple negative phenotype 
together with dual expression of luminal and basal cytokeratins are also well recognized 
features of metaplastic carcinoma14, 76. Breast PA is often associated with a papillary lesion 
similar to other low-grade metaplastic carcinomas and adenomyoepithelioma. These 
tumours may represent a form of low-grade indolent breast tumour that resides at the lower 
end of a spectrum of matrix-producing metaplastic carcinoma featuring prominent stromal 
metaplastic differentiation and low-grade cytological features. Histological features that may 
favour PA over matrix producing metaplastic carcinoma include small size, underlying 
benign papillary structure, absence of significant cytonuclear atypia, scant myxoid stroma 
and presence of bone. The diagnosis of breast PA can be difficult on core biopsy. We75 and 
others63 have reported breast PA as matrix-producing metaplastic carcinoma on preoperative 
core biopsy that was followed by a benign diagnosis following surgical excision. To avoid 
such inconsistency and in view of the above as well as the lack of molecular evidence to 
help characterise these lesions as benign or malignant, we propose to consider them as 
lesions of uncertain malignant potential.
B-Mammary Cylindroma
Although low grade adenoid cystic carcinomas of the breast is considered as malignant 
tumour akin to their salivary gland counterpart, a tumour showing prominent cylindromatous 
differentiation in the breast is considered as a benign tumour. Historically breast adenoid 
cystic carcinomas exhibiting prominent basaloid features and producing a characteristic 
cylindromatous pattern have been recognized in the breast and the terms adenoid cystic 
carcinoma and cylindroma have been used interchangeably77, 78. More recent publications, 
mostly case reports, have considered that such lesions were similar to the benign skin 
counterpart, hence the use of the term ‘dermal analogue tumour79–83. In terms of features 
unique to breast cylindroma Albores-Saavedra et al79 described that areas of normal 
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lactiferous duct can be observed transitioning into cylindroma. They postulate that this 
implies a site of origin of the tumour from within the breast. Infiltration of the surrounding 
tissue has been reported in breast cylindroma, but this feature has been termed ‘pseudo-
infiltration’ rather than recognized as an indication of a true malignant nature of the 
lesion80, 81, 83 without additional supporting evidence. Basaloid, solid variants of adenoid 
cystic carcinoma of the breast can mimic breast cylindroma including nodular and trabecular 
growth patterns and the presence of basement membrane like material. Both adenoid cystic 
carcinoma and breast cylindroma share the same immunoprofile with triple negative 
phenotype, p63 and strong c-kit expression84. This shared c-kit positivity between 
cylindroma and adenoid cystic carcinoma may add further weight to Fehr et al.’s opinion 
that cylindroma and ACC may originate from a shared common progenitor cell80. We 
believe that the lack of cytological atypia, mitotic activity and focal preservation of 
myoepithelial cells in breast cylindroma represent features of indolence, inherent in such a 
degree of differentiation, as seen in other low-grade malignant tumours akin to low-grade 
adenoid cystic carcinoma rather than features defining a benign biological nature of a breast 
tumour. This may assist in avoiding variation in diagnosis between different centres and also 
between core biopsy and surgical excision diagnosis as reported by us and others79, 85. 
These tumours can be considered as lesions of uncertain malignant potential to reflect the 
current uncertain nature of these tumours.
3- Microglandular adenosis and atypical microglandular adenosis
Microglandular adenosis (MA) is a rare breast lesion featuring haphazardly infiltrating 
small, uniform, rounded, open glands lined by a single layer of bland-looking cells, 
containing eosinophilic secretions and irregularly distributed in fibrous or adipose tissue. 
Glands of MA show diffuse strong S100 positivity and lack peripheral myoepithelial cells, 
but are surrounded by basement membrane. Atypical microglandular adenosis (AMA) shows 
pleomorphic glands, microacini with luminal bridging and small solid clusters with mild 
cytological atypia, prominent nucleoli, reduced intraluminal secretions and occasional 
mitotic figures86–88. Several independent studies have reported an association between MA 
and AMA and invasive carcinoma mainly of triple negative subtype87, 89–92. Molecular 
analysis revealed that MA is a clonal and neoplastic lesion harbouring recurrent mutations of 
TP53 and other cancer driver genes93. The nature of these rare lesions remains less 
characterised in the literature and emerging evidence favour their neoplastic nature with the 
implication that they comprise non-obligate precursors of triple negative breast carcinoma. 
The absence of peripheral myoepithelial cells in addition to the infiltrative nature, 
cytological atypia of AMA and the extent of the lesions make management problematic.
SUMMARY
In conclusion, there are always uncertainties in clinical practice - in classification, clinical 
behaviour and management of breast lesions. In this review we highlight the existence of 
rare borderline breast lesions of yet undefined nature and uncertain clinical behaviour that 
are often associated with variable diagnostic opinion and management. These include breast 
lesions of uncertain malignant nature and those with uncertain/negligible metastatic 
potential. Recognising this uncertainty can help improve consistency of management and 
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reduce the chance of under-treatment or over-treatment resulting from definite categorization 
as benign or malignant. Clinicians and patients can make informed decisions about 
management of these breast lesions in view of the information regarding the uncertainty of 
their nature. Further studies of these lesions are warranted.
References
1. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally 
occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell 
characteristics. Cancer Res. 2009; 69(10):4116–24. [PubMed: 19435916] 
2. van Deurzen CH, Lee AH, Gill MS, et al. Metaplastic breast carcinoma: tumour histogenesis or 
dedifferentiation? J Pathol. 2011; 224(4):434–7. [PubMed: 21462188] 
3. Wang X, Mori I, Tang W, et al. Metaplastic carcinoma of the breast: p53 analysis identified the same 
point mutation in the three histologic components. Mod Pathol. 2001; 14(11):1183–6. [PubMed: 
11706082] 
4. Kaufman MW, Marti JR, Gallager HS, Hoehn JL. Carcinoma of the breast with pseudosarcomatous 
metaplasia. Cancer. 1984; 53(9):1908–17. [PubMed: 6322962] 
5. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in 
the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 
2003; 36(Suppl 1):73–84. [PubMed: 14521517] 
6. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for 
basal tumor development in BRCA1 mutation carriers. Nat Med. 2009; 15(8):907–13. [PubMed: 
19648928] 
7. Tsubochi H, Sato N, Kaimori M, Imai T. Osteosarcomatous differentiation in lung metastases from a 
malignant phyllodes tumour of the breast. J Clin Pathol. 2004; 57(4):432–4. [PubMed: 15047752] 
8. Tan, PH.; Tse, G.; Lee, A.; Simpson, J.; Hanby, AM., editors. Fibroepithelial Tumours. 4. IARC 
press; Lyon: 2012. 
9. Zhang C, Quddus MR, Sung CJ. Atypical adenomyoepithelioma of the breast: diagnostic problems 
and practical approaches in core needle biopsy. Breast J. 2004; 10(2):154–5. [PubMed: 15009045] 
10. Loose JH, Patchefsky AS, Hollander IJ, Lavin LS, Cooper HS, Katz SM. Adenomyoepithelioma of 
the breast. A spectrum of biologic behavior. Am J Surg Pathol. 1992; 16(9):868–76. [PubMed: 
1384377] 
11. Rosen PP, Ernsberger D. Low grade adenosquamous carcinoma. A variant of metaplastic 
mammary carcinoma. Am J Surg Pathol. 1987; 11:351–8. [PubMed: 3578645] 
12. Rito M, Schmitt F, Pinto AE, Andre S. Fibromatosis-like metaplastic carcinoma of the breast has a 
claudin-low immunohistochemical phenotype. Virchows Arch. 2014; 465(2):185–91. [PubMed: 
24903673] 
13. Rakha EA, Gandhi N, Climent F, et al. Encapsulated papillary carcinoma of the breast: an invasive 
tumor with excellent prognosis. Am J Surg Pathol. 2011; 35(8):1093–103. [PubMed: 21753694] 
14. Eusebi, V.; Foschini, MP., editors. Pleomorphic Adenoma. 4. IARC press; Lyon: 2012. 
15. Azzopardi, JG. Problems in Breast Pathology. London: WB Saunders; 1979. Infiltrating 
epitheliosis; p. 174-87.
16. Gricouroff G, Zajdela A, Herrerabendana B. Mammary Cylindroma. Bulletin de l’Association 
francaise pour l’etude du cancer. 1964; 51:277–82.
17. Williams ED. Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors. Int J 
Surg Pathol. 2000; 8(3):181–3. [PubMed: 11493987] 
18. Hofman V, Lassalle S, Bonnetaud C, et al. Thyroid tumours of uncertain malignant potential: 
frequency and diagnostic reproducibility. Virchows Arch. 2009; 455(1):21–33. [PubMed: 
19543912] 
19. Balabaud C, Bioulac-Sage P, Ferrell L, et al. Well-differentiated hepatocellular neoplasm of 
uncertain malignant potential. Hum Pathol. 2015; 46(4):634–5. [PubMed: 25661243] 
Rakha et al. Page 10
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
20. Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential 
(STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009; 33(7):992–1005. 
[PubMed: 19417585] 
21. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support 
its excellent prognosis. J Clin Oncol. 2010; 28(1):99–104. [PubMed: 19917872] 
22. Rakha EA, Tun M, Junainah E, Ellis IO, Green A. Encapsulated papillary carcinoma of the breast: 
a study of invasion associated markers. J Clin Pathol. 2012; 65(8):710–4. [PubMed: 22554960] 
23. Collins, L.; O’Malley, FP.; Visscher, D.; Moriya, T.; Ichihara, S.; Reis-Filho, JS., editors. 
Encapsulated Papillary Carcinoma. 4. IARC press; Lyon: 2012. 
24. Esposito NN, Dabbs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast in situ or 
invasive? A basement membrane study of 27 cases. Am J Clin Pathol. 2009; 131(2):228–42. 
[PubMed: 19141383] 
25. Rakha EA, Varga Z, Elsheik S, Ellis IO. High-grade encapsulated papillary carcinoma of the 
breast: an under-recognized entity. Histopathology. 2015; 66(5):740–6. [PubMed: 25382726] 
26. Soo K, Tan PH. Low-grade adenosquamous carcinoma of the breast. J Clin Pathol. 2013; 66(6):
506–11. [PubMed: 23268316] 
27. Wilsher MJ. Adenosquamous proliferation of the breast and low grade adenosquamous carcinoma: 
a common precursor of an uncommon cancer? Pathology. 2014; 46(5):402–10. [PubMed: 
24842378] 
28. Tan QT, Chuwa EW, Chew SH, Lim-Tan SK, Lim SH. Low-grade adenosquamous carcinoma of 
the breast: A diagnostic and clinical challenge. International journal of surgery. 2015; 19:22–6. 
[PubMed: 25986061] 
29. Boecker W, Stenman G, Loening T, et al. Differentiation and histogenesis of syringomatous tumour 
of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin. 
Histopathology. 2014
30. Rakha EA, Tan PH, Varga Z, et al. Prognostic factors in metaplastic carcinoma of the breast: a 
multi-institutional study. Br J Cancer. 2015; 112(2):283–9. [PubMed: 25422911] 
31. Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a 
dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 1999; 85(10):
2170–82. [PubMed: 10326695] 
32. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like) spindle cell carcinoma of 
the breast. Am J Surg Pathol. 2001; 25(8):1009–16. [PubMed: 11474284] 
33. Dwyer JB, Clark BZ. Low-Grade Fibromatosis-like Spindle Cell Carcinoma of the Breast. Arch 
Pathol Lab Med. 2015; 139(4):552–7. [PubMed: 25822766] 
34. Tse GM, Tan PH, Lui PC, Putti TC. Spindle cell lesions of the breast--the pathologic differential 
diagnosis. Breast Cancer Res Treat. 2008; 109(2):199–207. [PubMed: 17636400] 
35. Rakha EA, Tan PH, Shaaban A, et al. Do primary mammary osteosarcoma and chondrosarcoma 
exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. 
Breast. 2013; 22(1):13–8. [PubMed: 23084962] 
36. Takano EA, Hunter SM, Campbell IG, Fox SB. Low-grade fibromatosis-like spindle cell 
carcinomas of the breast are molecularly exiguous. J Clin Pathol. 2015
37. Ang MK, Ooi AS, Thike AA, et al. Molecular classification of breast phyllodes tumors: validation 
of the histologic grading scheme and insights into malignant progression. Breast Cancer Res Treat. 
2011; 129(2):319–29. [PubMed: 20945089] 
38. Jara-Lazaro AR, Tan PH. Molecular pathogenesis of progression and recurrence in breast 
phyllodes tumors. American journal of translational research. 2009; 1(1):23–34. [PubMed: 
19966935] 
39. Wei J, Tan YT, Cai YC, et al. Predictive factors for the local recurrence and distant metastasis of 
phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center. Chinese 
journal of cancer. 2014; 33(10):492–500. [PubMed: 25104281] 
40. Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumors of the breast: the role of pathologic 
parameters. Am J Clin Pathol. 2005; 123(4):529–40. [PubMed: 15743740] 
41. Nadelman CM, Leslie KO, Fishbein MC. “Benign,” metastasizing adenomyoepithelioma of the 
breast: a report of 2 cases. Arch Pathol Lab Med. 2006; 130(9):1349–53. [PubMed: 16948523] 
Rakha et al. Page 11
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
42. Lakhani, SR.; Hayes, M.; Eusebi, V., editors. Adenomyoepithelioma and adenomyoepithelioma 
with carcinoma. 4. IARC press; Lyon: 2012. 
43. Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 
phyllodes tumors of the breast. Ann Surg Oncol. 2007; 14(10):2961–70. [PubMed: 17562113] 
44. Asoglu O, Ugurlu MM, Blanchard K, et al. Risk factors for recurrence and death after primary 
surgical treatment of malignant phyllodes tumors. Ann Surg Oncol. 2004; 11(11):1011–7. 
[PubMed: 15525831] 
45. Al-Masri M, Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M. Phyllodes tumor of 
the breast: role of CD10 in predicting metastasis. Ann Surg Oncol. 2012; 19(4):1181–4. [PubMed: 
22006372] 
46. Chen WH, Cheng SP, Tzen CY, et al. Surgical treatment of phyllodes tumors of the breast: 
retrospective review of 172 cases. J Surg Oncol. 2005; 91(3):185–94. [PubMed: 16118768] 
47. Grimes MM. Cystosarcoma phyllodes of the breast: histologic features, flow cytometry analysis 
and clinical correlations. Mod Pathol. 1992; 5:232–9. [PubMed: 1323101] 
48. Salvadori B, Cusumano F, del RBo, et al. Surgical treatment of phyllodes tumours of the breast. 
Cancer. 1989; 63:2532–6. [PubMed: 2541890] 
49. Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K. The treatment and prognosis of 
patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996; 77(5):910–6. 
[PubMed: 8608483] 
50. Eberle C, Piscuoglio S, Rakha E, et al. Massively Parallel Sequencing Analysis of Infiltrating 
Epitheliosis of the breast. Mod Pathol. 2015; 28(Suppl 2):42A.
51. Yamaguchi R, Maeshiro K, Ellis IO, et al. Infiltrative epitheliosis of the breast. J Clin Pathol. 2012; 
65(8):766–8. [PubMed: 22461653] 
52. Eusebi V, Millis RR. Epitheliosis, infiltrating epitheliosis, and radial scar. Semin Diagn Pathol. 
2010; 27(1):5–12. [PubMed: 20306826] 
53. Agnantis NJ, Maounis N, Priovolou-Papaevangelou M, Baltatzis I. Pleomorphic adenoma of the 
human female breast. Pathol Res Pract. 1992; 188(1–2):235–40. discussion 40–1. [PubMed: 
1317557] 
54. Kim M, Lee DW, Im J, et al. Adenoid cystic carcinoma of the breast: a case series of six patients 
and literature review. Cancer research and treatment: official journal of Korean Cancer 
Association. 2014; 46(1):93–7. [PubMed: 24520228] 
55. Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical 
features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands 
versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer. 
2012; 118(16):3945–53. [PubMed: 22179977] 
56. Piscuoglio S, Hodi Z, Katabi N, et al. Are acinic cell carcinomas of the breast and salivary glands 
distinct diseases? Histopathology. 2015
57. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. Expression of reciprocal 
hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer 
Res. 1997; 57(1):13–7. [PubMed: 8988031] 
58. Voz ML, Agten NS, Van de Ven WJ, Kas K. PLAG1, the main translocation target in pleomorphic 
adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res. 2000; 60(1):106–13. 
[PubMed: 10646861] 
59. Sato K, Ueda Y, Shimasaki M, et al. Pleomorphic adenoma (benign mixed tumor) of the breast: a 
case report and review of the literature. Pathol Res Pract. 2005; 201(4):333–9. [PubMed: 
15991841] 
60. Leekha N, Muralee M, Mathews A, Preethi TR, Ahamed MI. Pleomorphic adenoma of breast-a 
case report and review of literature. Indian J Surg Oncol. 2014; 5(2):152–4. [PubMed: 25114471] 
61. Brogi, E. Myoepithelial Neoplasms. In: Rosen, P., editor. Rosen’s Breast Pathology. 4. 
Philadelphia: Lippincott Williams & Wilkins, a Wolter Kluwer business; 2014. p. 153-82.
62. Rosen, PP. Myoepithelial Neoplasms. 3. Philadelphia: Lippincott Williams & Wilkins; 2009. 
63. Djakovic A, Engel JB, Geisinger E, Honig A, Tschammler A, Dietl J. Pleomorphic adenoma of the 
breast initially misdiagnosed as metaplastic carcinoma in preoperative stereotactic biopsy: a case 
Rakha et al. Page 12
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
report and review of the literature. Eur J Gynaecol Oncol. 2011; 32(4):427–30. [PubMed: 
21941969] 
64. John BJ, Griffiths C, Ebbs SR. Pleomorphic adenoma of the breast should be excised with a cuff of 
normal tissue. Breast J. 2007; 13(4):418–20. [PubMed: 17593049] 
65. Diaz NM, McDivitt RW, Wick MR. Pleomorphic adenoma of the breast: a clinicopathologic and 
immunohistochemical study of 10 cases. Hum Pathol. 1991; 22(12):1206–14. [PubMed: 1660850] 
66. Soreide JA, Anda O, Eriksen L, Holter J, Kjellevold KH. Pleomorphic adenoma of the human 
breast with local recurrence. Cancer. 1988; 61(5):997–1001. [PubMed: 2827885] 
67. Hayes MM, Lesack D, Girardet C, Del Vecchio M, Eusebi V. Carcinoma ex-pleomorphic adenoma 
of the breast. Report of three cases suggesting a relationship to metaplastic carcinoma of matrix-
producing type. Virchows Arch. 2005; 446(2):142–9. [PubMed: 15583933] 
68. Skalova A, Altemani A, Di Palma S, et al. Pleomorphic adenoma of the salivary glands with 
intravascular tumor deposits: a diagnostic pitfall. Am J Surg Pathol. 2012; 36(11):1674–82. 
[PubMed: 23073326] 
69. Collina G, Eusebi V, Carasoli PT. Pleomorphic adenoma with lymph-node metastases report of two 
cases. Pathol Res Pract. 1989; 184(2):188–93. [PubMed: 2540483] 
70. Vivian MA, Sahni VA, Lowe AC, Silverman SG. Benign metastasizing pleomorphic adenoma 
presenting as a solitary kidney mass: imaging features. Urology. 2012; 80(2):e17–8. [PubMed: 
22743258] 
71. Singhal A, Shrago SS, Li SF, Huang Y, Kohli V. A hepatic metastasis from pleomorphic adenoma 
of salivary gland: an unusual presentation. Hepato-gastroenterology. 2010; 57(98):330–3. 
[PubMed: 20583437] 
72. Bhutta MF, Dunk L, Molyneux AJ, Tewary A. Parotid pleomorphic adenoma with solitary renal 
metastasis. The British journal of oral & maxillofacial surgery. 2010; 48(1):61–3. [PubMed: 
19386401] 
73. Bae CH, Kim YD, Song SY. Benign pleomorphic adenoma of the soft palate metastasizing to the 
sphenoid sinus. Clinical and experimental otorhinolaryngology. 2010; 3(3):172–5. [PubMed: 
20978542] 
74. Sit KY, Chui WH, Wang E, Chiu SW. Multiple pulmonary metastases from benign pleomorphic 
adenoma. Asian cardiovascular & thoracic annals. 2008; 16(1):62–4. [PubMed: 18245710] 
75. Rakha EA, Aleskandarany MA, Samaka RM, Hodi Z, Lee AH, Ellis IO. Pleomorphic adenoma-
like tumour of the breast. Histopathology. 2015
76. Genelhu MC, Cardoso SV, Gobbi H, Cassali GD. A comparative study between mixed-type 
tumours from human salivary and canine mammary glands. BMC Cancer. 2007; 7:218. [PubMed: 
18045453] 
77. Kutnahorsky R, Tortel MC, Burger JP, et al. Adenoid cystic carcinoma or cylindroma of the breast. 
General review in light of one case report. J Gynecol Obstet Biol Reprod (Paris). 1991; 20(7):908–
12. [PubMed: 1665159] 
78. Eufemio G, Villaflor VV. Adenoid Cystic Carcinoma (Cylindroma) of Breast. Acta medica 
Philippina. 1965; 1:212–4. [PubMed: 14319110] 
79. Albores-Saavedra J, Heard SC, McLaren B, Kamino H, Witkiewicz AK. Cylindroma (dermal 
analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic 
carcinoma of the breast. Am J Clin Pathol. 2005; 123(6):866–73. [PubMed: 15899777] 
80. Mahmoud A, Hill DH, O’Sullivan MJ, Bennett MW. Cylindroma of the breast: a case report and 
review of the literature. Diagn Pathol. 2009; 4:30. [PubMed: 19725978] 
81. Gokaslan ST, Carlile B, Dudak M, Albores-Saavedra J. Solitary cylindroma (dermal analog tumor) 
of the breast: a previously undescribed neoplasm at this site. Am J Surg Pathol. 2001; 25(6):823–6. 
[PubMed: 11395563] 
82. Okamoto Y, Sumiyama Y, Arima Y, et al. A case of adenoid cystic carcinoma (ACC) of the breast 
and review of the utility of preoperative imaging diagnose. Breast Cancer. 2001; 8(1):84–9. 
[PubMed: 11180772] 
83. Nonaka D, Rosai J, Spagnolo D, Fiaccavento S, Bisceglia M. Cylindroma of the breast of skin 
adnexal type: a study of 4 cases. Am J Surg Pathol. 2004; 28(8):1070–5. [PubMed: 15252315] 
Rakha et al. Page 13
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
84. Hill PA. c-kit expression in adenoid cystic carcinoma of the breast. Pathology. 2004; 36(4):362–4. 
[PubMed: 15370139] 
85. Taghipour S, Shiryazdi SM, Sharahjin NS. Cylindroma of the breast in a 72-year-old woman with 
fibrocystic disease first misdiagnosed as a malignant lesion in imaging studies. BMJ case reports. 
2013; 2013
86. Rosen PP. Microglandular adenosis: a benign lesion simulating invasive mammary carcinoma. Am 
J Surg Pathol. 1983; 7:137–44. [PubMed: 6859388] 
87. Zhong F, Bi R, Yu B, et al. Carcinoma arising in microglandular adenosis of the breast: triple 
negative phenotype with variable morphology. International journal of clinical and experimental 
pathology. 2014; 7(9):6149–56. [PubMed: 25337263] 
88. Rakha EA, Lee AH, Sheeran R, et al. Breast Neoplasms with Dermal Analogue Differentiation 
(Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. Pathobiology. 
2015; 82:171–77.
89. Falleti J, Coletti G, Rispoli E, et al. Acinic cell carcinoma of the breast arising in microglandular 
adenosis. Case reports in pathology. 2013; 2013:736048. [PubMed: 24369519] 
90. Shui R, Yang W. Invasive breast carcinoma arising in microglandular adenosis: a case report and 
review of the literature. Breast J. 2009; 15(6):653–6. [PubMed: 19824997] 
91. Salarieh A, Sneige N. Breast carcinoma arising in microglandular adenosis: a review of the 
literature. Arch Pathol Lab Med. 2007; 131(9):1397–9. [PubMed: 17824796] 
92. Acs G, Simpson JF, Bleiweiss IJ, et al. Microglandular adenosis with transition into adenoid cystic 
carcinoma of the breast. Am J Surg Pathol. 2003; 27(8):1052–60. [PubMed: 12883237] 
93. Guerini-Rocco E, Piscuoglio S, Ng C, et al. Massively Parallel Sequencing Reveals That 
Microglandular Adenosis As a Clonal Neoplastic Lesion of Triple-Negative Phenotype. Mod 
Pathol. 2015; 28(Suppl 2):47A.
Rakha et al. Page 14
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Panel A shows a case of low grade adenosquamous metaplastic carcinoma. Panels B and C 
show a case of low grade fibromatosis like metaplastic carcinoma. Bother cases show bland 
cytological features, cellularity and infiltrative pattern not significantly different to those 
seen in fibromatosis (panel D).
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Figure 2. 
Infiltrating epitheliosis (IE). Panels A and B show morphological features of IE with 
epithelial proliferation, infiltrative appearances and desmoplastic-like stroma. Panels C to F 
showed immunohistochemical expression of myoepithelial marker (p63, panel C), luminal 
(CK18; panel D) and basal (CK5/6 panel E and CK14; panel F) cytokeratins.
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Table 1
Key Features of the breast lesions of limited metastatic potential
Entity Key features
Encapsulated papillary 
carcinoma (EPC)
Characterised by fibrovascular cores covered by proliferating malignant epithelial cells forming well-
circumscribed/dilated ductal profile pattern and surrounded by a thick fibrous capsule. Cystic with focal 
solid areas and may be multinodular. Low to intermediate grade nuclei. Typically strongly positive for 
nuclear ER and negative for HER2. Cases maintaining myoepithelial cells at the periphery can be 
considered as DCIS. However, >80% completely lack myoepithelial cells throughout and behave in an 
indolent invasive pattern with reported lymphovascular invasion (3%), nodal metastasis (3%) and local in-
breast or chest wall recurrence (7%) occurring in cases lacking coexisting conventional-type invasive 
carcinomas. Current consensus is to be managed as in situ disease but rare invasive behaviour may be 
expected. Recurrence is associated with aggressive behaviour. Occasional cases featuring high grade 
nuclei or focal micropapillary pattern can be considered as invasive disease.
Solid papillary carcinoma (SPC) Similar to EPC but features solid growth pattern and frequent neuroendocrine and mucinous 
differentiation, nuclear palisading and cell spindling and more often multinodular, lack peripheral fibrous 
capsule and associated with coexisting invasive carcinoma. Definition of invasion in SPC completely 
lacking myoepithelial cells and show multinodularity with closely apposed clusters/duct-like structures is 
often problematic. Although current consensus is to consider SPC as an in situ disease, the WHO working 
group define invasive SPC by the presence of geographical jigsaw pattern with more ragged and irregular 
margins coupled with complete lack of myoepithelial cells. As the growth pattern of SPC is variable and 
distinction of cases with complex architecture from those without is subjective, Controversy regarding 
categorisation of individual cases exists and should be acknowledged.
Low-grade adenosquamous 
carcinoma (LG-ASC)
A rare variant of MBC featuring glandular and tubular structures and solid nests of squamous cells in a 
spindle cell background and commonly arises in association with benign proliferative complex sclerosing 
and papillary breast lesions. It is often difficult to be differentiated from the proliferative phase of these 
benign fibrosclerosing lesions. Their entrapped, compressed glandular elements imitate the syringoid 
glands of LG-ASC and their radiating configuration may appear infiltrative at the periphery in addition to 
squamous metaplasia. Features favouring malignancy include extension into surrounding breast tissue, ER-
negativity, lack of myoepithelial cells around some glandular/tubular structures that show dual expression 
of low and high molecular weight CKs, and scattered squamous (p63+) islands in the dense spindle cell 
background with peripheral prominent inflammatory component. However, immunoreactivity for 
myoepithelial cells at the edge of some tumour islands can be seen and that adenosquamous proliferation 
is morphologically and immunohistochemically indistinguishable from those seen in the reactive-looking 
fibrosclerosing breast lesions. Pure LG-ASC has a favourable prognosis with very rare incidence of lymph 
node or distant metastasis and it needs to be differentiated from the aggressive high-grade adenosquamous 
MBC. LG-ASC and syringomatous adenoma of the nipple are locally aggressive lesions, sharing 
morphological and molecular features as well as the propensity for local recurrence, differing only in their 
location and designation.
Low grade fibromatosis-like 
metaplastic carcinoma
Infiltrative tumour with entrapped normal breast structures. Low grade spindle cell proliferation with pale 
eosinophilic cytoplasm and slender nuclei with tapered edges and finely distributed chromatin but with 
focal plump fusiform and polygonal tumour cells, with more rounded nuclei arranged in “epithelioid” 
clumps mainly seen centrally in the tumour. Variable cellularity and collagenisation, DCIS rarely present 
(10–15%). Scattered inflammatory infiltrate comprised of lymphocytes and plasma cells with occasional 
lymphoid follicles at the edges of the tumours. Often difficult to be differentiated from other BSCT 
including fibromatosis, nodular fasciitis, myofibroblastoma, solitary fibrous tumour and scar. IHC: 
typically expression of cytokeratins including low and high molecular weight and p63. CKs+ cells usually 
appear as cords or sheets of polygonal cells; rarely as isolated positive cells. SMA is often positive 
particularly in CK negative cells. Typically negative for CD34, hormone receptor, HER2 and desmin. They 
are characterised by low genomic instability, and do not share CNAs with other metaplastic carcinomas. 
These tumours can be locally aggressive with an increased incidence of local recurrence, but the potential 
for lymph node or distant metastasis is very low. Events are associated with higher grade lesions which are 
often large in size.
Borderline Phyllodes Tumour Although features of benign and malignant phyllodes are largely defined and it is often easy to be 
differentiated in most cases, some cases of phyllodes tumour (7%–34%) show overlapping features and 
exhibit some but not all featuring characteristics of malignant phyllodes tumours and lack frank 
sarcomatous stroma. Although these tumours not labelled as malignant and are associated with a lower 
rate of local recurrence than malignant tumours (14%–25%), they exhibit the ability to recur at distant sites 
despite being a rare event. The subjective diagnostic features of these tumours coupled with the ability to 
metastasise make predicting behaviour of these tumours in routine practice problematic.
Atypical adenomyoepithelioma Similar to phyllodes tumours, features and behaviour of benign and malignant adenomyoepitheliomas are 
largely defined. However, some cases show features of benign adenomyoepithelioma with focal or slight to 
moderate increase of mitotic figures and cytonuclear atypia in the proliferating myoepithelial cell 
population. The behaviour of these cases is difficult to predict and lymph node metastasis has been 
reported in such cases lacking overt features of malignancy. Therefore it should be acknowledged that a 
diagnosis of atypical adenomyoepithelioma should not exclude the possibility of invasive behaviour in a 
small proportion of cases which is not expected in benign cases and not sufficient for managing the case as 
an invasive tumour.
Histopathology. Author manuscript; available in PMC 2016 August 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rakha et al. Page 18
MBC= metaplastic breast carcinoma. BSCL=breast spindle cell lesion, CAN=copy number alteration
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Table 2
Key Features of the breast lesions of uncertain malignant nature
Entity Key features
Infiltrating epitheliosis (IE) IE is a rare lesion characterized by infiltrating epithelial islands, solid clusters, ducts and duct-like structures 
immersed in a scleroelastotic stroma. Proliferating cells feature architectural and cytological patterns and 
immunohistochemical profile reminiscent of those of usual ductal hyperplasia. The infiltrative nature and the 
lack of peripheral myoepithelial cells raise the concern that IE is a form of invasive low-grade malignant 
neoplasm, with some similarities to LG-ASC exist. However, the immunoprofile, benign cytonuclear features, 
the absence of an in situ carcinoma and focal preservation of peripheral myoepithelial cells support the current 
view that IE is a form of benign exaggerated hyperplastic process. No events related to a malignant behaviour 
have been reported in cases diagnosed as IE and the evidence to describe its nature and predict its behaviour 
compared to benign hyperplastic or low-grade malignant process remains lacking. Therefore the uncertain 
nature and behaviour of such lesions should be acknowledged.
Mammary Pleomorphic 
Adenoma (PA)
Breast PA is often associated with a papillary lesion similar to other low-grade MBC and 
adenomyoepithelioma. Despite the perceived indolent benign clinical behaviour of breast PA, local 
recurrences have been reported in the few published cases and cytologically malignant features characteristic 
of conventional mammary-type carcinomas have been demonstrated in PA and categorised as “carcinoma ex 
pleomorphic adenoma”. In the more common PA in the salivary gland, lymphovascular invasion and distant 
metastasis have been reported in histologically benign cases. Absence of peripheral myoepithelial cells is a 
feature of breast PA. These tumours may represent a form of low-grade indolent breast tumour that resides at 
the lower end of a spectrum of matrix-producing MBC featuring prominent stromal metaplastic differentiation 
and low-grade cytological features. These tumours are best regarded as PA-like tumours of the breast to reflect 
the uncertainty of their nature and behaviour
Mammary Cylindroma These tumours may represent a variant of low grade adenoid cystic carcinomas of the breast with prominent 
cylindromatous differentiation. The behaviour and origin of breast cylindroma may not be the same as the 
dermal counterparts and breast tumours show infiltration of the surrounding tissue. Both adenoid cystic 
carcinoma and breast cylindroma share the same immunoprofile with triple negative phenotype, p63 and 
strong c-kit expression. These tumours can be considered as lesions of uncertain malignant nature to reflect 
the current uncertainty regarding the nature and behaviour of these tumours.
Microglandular adenosis 
(MGA) and atypical 
microglandular adenosis
Despite the infiltrative nature and the lack of peripheral myoepithelial cells around the proliferating glands of 
MGA, the indolent clinical behaviour in the limited number published in literature and the bland cytological 
features render the benign nature of MGA. However, some cases show cytonuclear atypia, frequently 
associated with ER-negative carcinomas, and the diffuse strong nuclear S100 positivity together with recent 
molecular evidence suggest that MGA is a neoplastic process. The nature and behaviour of MGA particularly 
when associated with atypia remain unknown and such uncertainty needs to be acknowledged.
MBC=metaplastic breast carcinoma
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